Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly

Pain Due to Certain Specified Procedures Clinical Trial

— FENTA  

Official title:

Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly With or Without Background Treatment.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02298582
• Other study ID #: DCIC/13/67
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: December 8, 2014
• Est. completion date: April 2018

Study information

• Verified date: May 2018
• Source: University Hospital, Grenoble
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety of the intranasal fentanyl in pain induced by wound care and rehabilitation in the elderly. The project would also provide a preliminary assessment of the effectiveness of intranasal fentanyl used in procedural pains.

Description:

This is a safety clinical trial. This trial is monocentric, open label, non-randomized.

Sixty elderly patients will be enrolled in this study, 30 with bedsore cares and 30 with rehabilitation sessions.

Six bedsore cares or rehabilitation sessions will be assessed for each subject. For each session, patient pain will be evaluated using a visual analogic scale VAS at different times, before session, 5 minutes then 20 minutes after the beginning of the session, and a last VAS 1 hour after the end of the session. During the two first sessions, patients do not receive Pecfent® to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care.

An evaluation of respiratory rate and of the level of sedation will occur at different time :

after 5 minutes then 20 minutes of care, at the end of the care session,at half an hour then one hour after the care session.

At the end of sessions,

• The nurse or physiotherapist will assess their satisfaction regarding the objectives achieved during the session with a four points verbal descriptor scale (very satisfied, satisfied, not much satisfied, not satisfied). They will also evaluate at the end of the four last session their satisfaction regarding the convenience of the use of pecfent® and its contribution towards care.

• Patients will assess their satisfaction regarding the course of the session with a verbal descriptor scale (VDS) and their level of anxiety felt during the session with a VAS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 58
• Est. completion date: April 2018
• Est. primary completion date: October 24, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 76 Years and older

Eligibility

Inclusion Criteria:

• Hospitalized geriatric patient requiring care or rehabilitation

• Patient with pain during treatment or mobilization. (VAS = 4)

• Written Informed consent

Exclusion Criteria:

• All unstable fractures

• Confusion: unable to assess their level of pain using a VAS.

• Contraindications to PecFent ® (. Hypersensitivity to the active substance or to any of the excipients listed in section Composition Use in patients who had never received treatment for opioid severe respiratory depression or severe obstructive pulmonary disease.)

• Person under legal protection

Related Conditions & MeSH terms

• Pain Due to Certain Specified Procedures

Intervention

Drug:
• intranasal fentanyl
During the two first sessions of care or rehabilitation, patients do not receive Pecfent® in order to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. A titration of PecFent will be done at each session

Locations

Country	Name	City	State
France	University hospital of Grenoble	Grenoble	Isere

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Grenoble

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of intranasal fentanyl as measured by the nature and frequency of adverse effects.	The nature and frequency of adverse effects will be described. The collection of adverse events will be first, with the collection of spontaneous patient complaints from nurses on the other hand, by systematic screening with the patient. Monitoring of respiratory rate and level of sedation will also be set up.	5 days after the last intake of fentanyl.
Secondary	Effectiveness of intranasal fentanyl in procedural pain using a VAS (Visual Analogic Scale) of pain.	VAS will be evaluated during each session at t0, t0+15min, t0+30min, and 1hour after the session (on average at 2 hours)	Evolution of the level of pain (VAS) since the beginning of care until one hour after the end of session (on average at 2 hours).
Secondary	Fentanyl impact on the goals of care as measured by a caregiver satisfaction scale.	At the end of each session of care or rehabilitation, it will be proposed to the caregiver, a scale measuring its satisfaction regarding the objectives achieved during the session.	At the end of session of care or rehabilitation (on average at 1 hour).
Secondary	Nurse or physiotherapist satisfaction regarding use of PecFent® as measured by a verbal descriptor scale	Nurse or physiotherapist evaluation satisfaction regarding the convenience of the use of pecfent® and its contribution towards care using a verbal descriptor scale	1 hour after the last intake of fentanyl
Secondary	Impact of PecFent® on patient feelings during care or rehabilitation sessions as measured by a verbal descriptor scale	Patient evaluation at the end of sessions: - Patient satisfaction regarding the course of the session with a VDS	At the end of Session of care or rehabilitation (on average at 1 hour).